Oaktree Acquisition Corp. III Life Sciences (OACCW) Financial Ratios
1 years of historical data (2024–2024) · Financial Services · Shell Companies
EV/EBITDA
10.81
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
0.11
—
5yr avg: N/A
ROE
0.7%
+0% vs avg
5yr avg: 0.7%
30Y Low1%·High1%
Debt/EBITDA
0.01
+0% vs avg
5yr avg: 0.01
30Y Low0.0·High0.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
OACCW Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Oaktree Acquisition Corp. III Life Sciences trades at 15.1x earnings, sitting at the 50th percentile of its historical range. Compared to the Financial Services sector median P/E of 13.6x, the stock trades at a premium of 11%.
| Metric | TTM | FY 2024 |
|---|---|---|
| Market Cap | $16M | — |
| Enterprise Value | $14M | — |
| P/E Ratio → | 15.13 | — |
| P/S Ratio | — | — |
| P/B Ratio | 0.11 | — |
| P/FCF | — | — |
| P/OCF | — | — |
P/E links to full P/E history page with 30-year chart
OACCW EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Oaktree Acquisition Corp. III Life Sciences's enterprise value stands at 10.8x EBITDA. The Financial Services sector median is 11.4x, placing the stock at a 5% discount on an enterprise-value basis.
| Metric | TTM | FY 2024 |
|---|---|---|
| EV / Revenue | — | — |
| EV / EBITDA | 10.81 | — |
| EV / EBIT | — | — |
| EV / FCF | — | — |
OACCW Profitability
Margins and return-on-capital ratios measuring operating efficiency
ROE of 0.7% is modest, trailing the sector median of 9.0%.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 |
|---|---|---|
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Profit Margin | — | — |
Return on Capital
| Metric | TTM | FY 2024 |
|---|---|---|
| ROE | 0.7% | 0.7% |
| ROA | 0.7% | 0.7% |
| ROIC | — | — |
| ROCE | -0.2% | -0.2% |
OACCW Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Oaktree Acquisition Corp. III Life Sciences carries a Debt/EBITDA ratio of 0.0x, which is very conservative (100% below the sector average of 4.3x). The company holds a net cash position — cash of $1M exceeds total debt of $11824, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 |
|---|---|---|
| Debt / Equity | 0.00 | 0.00 |
| Debt / EBITDA | 0.01 | 0.01 |
| Net Debt / Equity | — | -0.01 |
| Net Debt / EBITDA | -1.01 | -1.01 |
| Debt / FCF | — | — |
| Interest Coverage | — | — |
Net cash position: cash ($1M) exceeds total debt ($11824)
OACCW Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Oaktree Acquisition Corp. III Life Sciences's current ratio of 2.14x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities.
| Metric | TTM | FY 2024 |
|---|---|---|
| Current Ratio | 2.14 | 2.14 |
| Quick Ratio | 2.14 | 2.14 |
| Cash Ratio | 1.87 | 1.87 |
| Asset Turnover | — | — |
| Inventory Turnover | — | — |
| Days Sales Outstanding | — | — |
OACCW Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Oaktree Acquisition Corp. III Life Sciences does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 6.6% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 |
|---|---|---|
| Dividend Yield | — | — |
| Payout Ratio | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 |
|---|---|---|
| Earnings Yield | 6.6% | — |
| FCF Yield | — | — |
| Buyback Yield | 0.0% | — |
| Total Shareholder Yield | 0.0% | — |
| Shares Outstanding | — | $25M |
Peer Comparison
Compare OACCW with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 OACCWYou | $16M | 15.1 | 10.8 | — | — | — | 0.7% | — | 0.0 |
 RLAY | $3B | -10.7 | — | — | 76.8% | -1971.6% | -41.1% | -37.3% | — |
 RXRX | $1B | -2.2 | — | — | -62.0% | -867.9% | -59.5% | -95.8% | — |
 BCTX | $6M | -0.0 | — | — | — | — | -363.0% | -1263.2% | — |
 IPOD | $151M | 47.4 | — | — | — | — | 1.7% | -0.2% | — |
 BX | $97B | 31.8 | 14.9 | 55.4 | 86.0% | 51.9% | 14.6% | 16.1% | 1.8 |
 KKR | $86B | 41.4 | 19.8 | 9.1 | 41.8% | 2.4% | 3.3% | 0.3% | 7.7 |
 APO | $78B | 18.6 | 6.3 | 10.5 | 88.5% | 34.4% | 12.2% | 16.0% | 1.2 |
 CG | $16B | 20.4 | 20.0 | 11.8 | 65.9% | 26.2% | 12.1% | 5.2% | 10.4 |
 ARES | $41B | 64.2 | 27.3 | 26.8 | 74.8% | 27.2% | 6.8% | 6.1% | 7.4 |
 TPG | $16B | 34.0 | 20.3 | 15.7 | 96.9% | 14.7% | 4.8% | 9.3% | 2.1 |
| Financial Services Median | — | 13.6 | 11.4 | 11.1 | 64.1% | 20.3% | 9.0% | 5.5% | 4.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 1 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
OACCW — Frequently Asked Questions
Quick answers to the most common questions about buying OACCW stock.
What is Oaktree Acquisition Corp. III Life Sciences's P/E ratio?
Oaktree Acquisition Corp. III Life Sciences's current P/E ratio is 15.1x. This places it at the 50th percentile of its historical range.
What is Oaktree Acquisition Corp. III Life Sciences's EV/EBITDA?
Oaktree Acquisition Corp. III Life Sciences's current EV/EBITDA is 10.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
What is Oaktree Acquisition Corp. III Life Sciences's ROE?
Oaktree Acquisition Corp. III Life Sciences's return on equity (ROE) is 0.7%. The historical average is 0.7%.
Is OACCW stock overvalued?
Based on historical data, Oaktree Acquisition Corp. III Life Sciences is trading at a P/E of 15.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
How much debt does Oaktree Acquisition Corp. III Life Sciences have?
Oaktree Acquisition Corp. III Life Sciences's Debt/EBITDA ratio is 0.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.